US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Celcuity Inc. - Common Stock
(NQ:
CELC
)
71.25
-2.37 (-3.22%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celcuity Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Why Celcuity Stock Was a Winner on Wednesday
↗
September 30, 2026
Its first commercialized drug is now available for qualified patients.
Via
The Motley Fool
Celcuity (CELC) Q2 2026 Earnings Call Transcript
↗
August 20, 2026
Revtopik launch underway with 80 oncology specialists supporting expansion into first-line treatment.
Via
The Motley Fool
Topics
Earnings
Celcuity Q2 Earnings Call Highlights
↗
August 13, 2026
Celcuity (NASDAQ:CELC) said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026...
Via
MarketBeat
Topics
Earnings
Celcuity Inc. (NASDAQ:CELC) Q1 Earnings Beat Forecasts, But Stock Drops on Phase 3 Data Focus
↗
May 14, 2026
Via
Chartmill
Topics
Earnings
Celcuity Inc. (NASDAQ:CELC) Reports Q4 Earnings Beat and Key FDA Priority Review for Gedatolisib
↗
March 25, 2026
Via
Chartmill
Topics
Earnings
Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript
↗
August 13, 2026
On Thursday, Celcuity (NASDAQ:CELC) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call...
Via
Benzinga
Topics
Earnings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
August 04, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm
August 04, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
August 03, 2026
From
Kirby McInerney LLP
Via
Business Wire
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
August 02, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
July 28, 2026
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
July 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm
July 21, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
July 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer
↗
July 15, 2026
Celcuity (NASDAQ:CELC) said the U.S. Food and Drug Administration has granted full approval to gedatolisib, now branded as REVTORPYK, for certain patients with advanced breast cancer, marking the...
Via
MarketBeat
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
↗
June 19, 2026
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s....
Via
InvestorPlace
Stay updated with the stocks that are on the move in today's pre-market session.
↗
June 02, 2026
Via
Chartmill
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
↗
May 30, 2026
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
Via
The Motley Fool
Topics
Regulatory Compliance
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
↗
May 17, 2026
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
↗
May 17, 2026
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Via
The Motley Fool
Topics
Regulatory Compliance
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
↗
May 17, 2026
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Via
The Motley Fool
Celcuity Q1 Earnings Call Highlights
↗
May 14, 2026
Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its...
Via
MarketBeat
Topics
Earnings
Celcuity (CELC) Q1 2026 Earnings Transcript
↗
May 14, 2026
Celcuity (CELC) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Intellectual Property
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
↗
May 10, 2026
This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.
Via
The Motley Fool
Topics
Regulatory Compliance
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
↗
May 10, 2026
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Via
The Motley Fool
Traders are paying attention to the gapping stocks in Monday's session.
↗
May 04, 2026
Via
Chartmill
Discover the top movers in Monday's pre-market session.
↗
May 04, 2026
Via
Chartmill
Why Celcuity Stock Popped on Monday
↗
April 27, 2026
An analyst initiated coverage of the biotech.
Via
The Motley Fool
Why Celcuity Stock Popped Today
↗
March 26, 2026
The cancer-focused biotech published its final set of figures for 2025.
Via
The Motley Fool
The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026
March 24, 2026
As of March 24, 2026, the financial markets are witnessing a tectonic shift that many analysts have dubbed "The Great Rotation." For the first time in over a decade, the small-cap Russell 2000 index is...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
World Trade
< Previous
1
2
3
4
5
6
7
Next >
